Transcode Therapeutics (RNAZ) Operating Income (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Operating Income came in at -$17.8 million in Q1 2026, down 459.89% YoY from $4.9 million in Q1 2025, and down 10.79% on a QoQ basis from -$16.0 million in Q4 2025.
Transcode Therapeutics (RNAZ) Operating Income (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Operating Income data on file, last reported at -$17.8 million in Q1 2026.
- Quarterly Operating Income fell 459.89% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.6 million (down 173.85% YoY) and the FY2025 annual result came in at -$28.0 million, down 78.66% from the prior year.
- Operating Income slipped to -$17.8 million in Q1 2026, from -$16.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$2.2 million in Q3 2024 to a low of -$17.8 million in Q1 2026.
- A 5-year average of -$5.8 million and a median of -$4.9 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income slumped 1224.03% — and 2024, when it jumped 59.22%.
- Tracing RNAZ's Operating Income over 5 years: stood at -$5.5 million in 2022, then increased by 25.44% to -$4.1 million in 2023, then fell by 24.28% to -$5.1 million in 2024, then slumped by 214.72% to -$16.0 million in 2025, then dropped by 10.79% to -$17.8 million in 2026.
- The last three Operating Income figures came in at -$17.8 million (Q1 2026), -$16.0 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | -6.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.76 Mn |
| Dec 31, 2025 | -16.03 Mn |
| Sep 30, 2025 | -4.56 Mn |
| Jun 30, 2025 | -4.22 Mn |
| Mar 31, 2025 | -3.17 Mn |
| Dec 31, 2024 | -5.09 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Jun 30, 2024 | -5.11 Mn |
| Mar 31, 2024 | -3.29 Mn |
| Dec 31, 2023 | -4.10 Mn |
| Sep 30, 2023 | -5.31 Mn |
| Jun 30, 2023 | -5.12 Mn |
| Mar 31, 2023 | -4.89 Mn |
| Dec 31, 2022 | -5.50 Mn |
| Sep 30, 2022 | -4.95 Mn |
| Jun 30, 2022 | -4.71 Mn |
| Mar 31, 2022 | -3.48 Mn |
| Dec 31, 2021 | -2.99 Mn |
| Sep 30, 2021 | -2.36 Mn |
| Jun 30, 2021 | -355,528.00 |